Immuron Ltd — Regulatory Filings 2005

Mar 15, 2005

March 16^th, 2005

Company Announcement Office Australian Stock Exchange Ltd (ASX) 4^th Floor, 20 Bridge Street Sydney NSW 2000

Dear Sir/Madam

Please find herewith a company announcement "Anadis appoints Innovex Australia as National Distributor for Travelan" for release and distribution to the market immediately.

Yours sincerely

for hagaty

per

CONOR GRAHAM Managing Director & CEO

Anadis appoints Innovex Australia as National Distributor for

Travelan

Anadis Ltd. is pleased to announce the appointment of Innovex Australia as the national distributor for Travelan, Anadis' patented product proven to actually reduce the risk of Travellers Diarrhoea rather than just treating the symptoms. Travellers' diarrhoea is the number one health problem in international travel in terms of frequency and economic impact.

"We are pleased to be working with Innovex to promote Travelan, a high quality product that we believe will serve an unmet need in the Australian marketplace," said Conor Graham, Chief Executive Officer, Anadis Ltd. "Innovex has an established nationwide distribution and sales capabilities, and its sales teams are well known to prescribers and pharmacists in Australia. We are confident that in working with Innovex, we will be able to accelerate the commercial success of Travelan nationally."

Travelan is currently in the process of international registration in the United States, the United Kingdom and the European Union. More information, regarding the registration of Travelan in parts of Asia is to be released when For more information in regards to Travelan, please see available. announcement "Travelan Presentation dated 19/10/2004".

About Innovex:

Innovex, a business unit of Quintiles Transnational, was established in Australia in 1997 and has offices in Sydney, Melbourne, Adelaide and Auckland. Quintiles Transnational helps improve healthcare worldwide by providing a broad range of professional services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. Headquartered near Research Triangle Park, North Carolina, Quintiles has offices in 50 countries and is the world's leading pharmaceutical services For more information visit the company's Web site at organization. www.quintiles.com.

About Anadis:

Anadis is a Melbourne-based biopharmaceutical company, focusing on Nutraceutical and Pharmaceutical product development. Anadis projects include EV-71 - a product against Enterovirus 71, a polio like disease affecting children in Taiwan and other parts of Asia, currently in the process of commercialisation; Pyloran, which has been clinically proven to reduce levels of bacteria in the stomach and reduce the symptoms of H.pylori associated gastritis - Anadis is also in early development of a H.pylori vaccine; Respiratory Protection technologies, a project in conjunction with the Australian Defence Forces and US Bio-Defence Organisations, initially focused on short-term immediate protection from airborne bacteria such as Anthrax and Plague, future civilian applications include Hay Fever and Asthma. Bio-Shield 10 a range of "bioshielding" technologies which protect delicate molecules, enzymes and proteins, initially targeted for use in the probiotic market, and research has begun into an Immune Stimulating Infant Formula initially for the Asian market.

For further information, please contact:

Steven Skorobogaty - General Manager Email steven.s@anadis.com.au +61 3 9358 6388 Conor Graham - Chief Executive Officer Email: conor.g@anadis.com.au +61 3 9358 6388 Arie Nudel - Investor Relations Email: arie.n@anadis.com.au +61 3 9358 6388

Visit our websites: www.anadis.com.au and www.travelan.com.au